Androgen deprivation therapy associated with increased risk for fatal heart attack
the ONA take:
Androgen deprivation therapy (ADT) and radiation therapy (RT) prolong survival in men with unfavorable-risk prostate cancer; however, evidence suggests that ADT is associated with nonfatal cardiovascular events.
Specifically, long-term follow-up of a randomized clinical trial that compared ADT and RT with RT alone showed that men with significant comorbidity, most commonly prior heart attack, who received ADT died earlier. These findings are published in a research letter in the Journal of the American Medical Association.
In this study, overall survival and death due to prostate cancer, fatal heart attack, and all other causes were analyzed. The study included 206 men with unfavorable-risk prostate cancer who were randomized to receive RT alone or RT and 6 months of ADT. The men were also categorized into subgroups based on prior comorbidity, including prior heart attack.
The findings demonstrate that prior heart attack is associated with an increased risk of fatal heart in men who receive ADT for unfavorable-risk prostate cancer.
Evidence suggests that androgen deprivation therapy is associated with nonfatal cardiovascular events.
Sign Up for Free e-newsletters
- Association Between Multiple Myeloma With VTE and Increased Mortality at 2, 5 Years
- Advanced Concepts in Oncology Navigation
- Building a Navigation Program: A Review of the Key Components
- From Disparities to Disclosure: A Discussion on Lesbians and Breast Cancer
- Difficult Conversations: The Role of Nurse Navigator
- Education May Better Equip Nurses to Hold End-of-Life Conversations in Advanced Cancer
- Avoiding the ED: Planned Strategies for Unplanned Urgent Cancer Care
- NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
- Accurate Understanding of Capacity May Improve Workflow, Efficiency in Infusion Suite
- Art as Palliative Care: Bedside Intervention Improves Pain, Anxiety, Mood in Hospitalized Cancer Patients
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|